CNS Pharmaceuticals, Inc. (CNSP)
NASDAQ: CNSP · Real-Time Price · USD
6.25
+0.05 (0.81%)
At close: Sep 2, 2025, 4:00 PM
6.41
+0.16 (2.56%)
After-hours: Sep 2, 2025, 7:43 PM EDT

CNS Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202018 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2020
Selling, General & Admin
5.425.614.775.974.684.39
Upgrade
Research & Development
10.159.2914.19.39.815.06
Upgrade
Operating Expenses
15.5814.918.8715.2714.499.45
Upgrade
Operating Income
-15.58-14.9-18.87-15.27-14.49-9.45
Upgrade
Interest Expense
-0.02-0.02-0.01-0.01-0.01-0
Upgrade
Interest & Investment Income
0.130.060.03---
Upgrade
EBT Excluding Unusual Items
-15.46-14.86-18.85-15.27-14.5-9.46
Upgrade
Pretax Income
-15.46-14.86-18.85-15.27-14.5-9.46
Upgrade
Net Income
-15.46-14.86-18.85-15.27-14.5-9.46
Upgrade
Net Income to Common
-15.46-14.86-18.85-15.27-14.5-9.46
Upgrade
Shares Outstanding (Basic)
00----
Upgrade
Shares Outstanding (Diluted)
00----
Upgrade
EPS (Basic)
-85.40-466.45----
Upgrade
EPS (Diluted)
-85.41-466.45----
Upgrade
Free Cash Flow
-20.86-17.12-14.14-10.56-13.54-7.34
Upgrade
Free Cash Flow Per Share
-115.24-537.39----
Upgrade
EBITDA
-15.57-14.9-18.86-15.26-14.47-9.44
Upgrade
D&A For EBITDA
0000.010.010.01
Upgrade
EBIT
-15.58-14.9-18.87-15.27-14.49-9.45
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q